A Study to Test the Safety/Tolerability of Increasing Doses of LNP1892 Versus Placebo in Healthy Male/Female Subjects

Inclusion Criteria: * Subjects will be; males or females (Group A3 only), of any ethnic origin, between 18 and 65 years of age (both inclusive) * Subjects will have a body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive * Subjects must be in good health, as determined by; medical history, physical examination, vital sign assessment, 12-lead electrocardiogram (ECG) * Clinical laboratory evaluations (congenital non-haemolytic hyperbilirubinaemia is not acceptable) * Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions Exclusion Criteria: * Male subjects who are not willing, or whose partners are not willing, to use appropriate contraception until 3 months after the final dosing occasion. * Female subjects who are of child-bearing potential; or those with tubal ligation. * Subjects who have donated; blood in the 3 months prior to screening, plasma in the 7 days prior to screening, platelets in the 6 weeks prior to screening * Subjects who;consume alcohol, cigarettes, tobacco and have a significant history of alcoholism or drug/chemical abuse as determined by the Investigator * Subjects who have used any non-prescribed systemic or topical medication, herbal remedies, Vitamin supplements, mineral supplements within 7 days of the first dose administration. * Subjects who have received any medications, within 30 days of the first dose administration, or any prescribed systemic or topical medication within 14 days of the first dose administration * Subjects who have an abnormality in heart rate, blood pressure, temperature or respiration rate. * Subjects with; a positive urine drug screen, a positive alcohol breath test result at screening or first admission. * Subjects who have an abnormality in the 12-lead ECG. * Female subjects who are pregnant or lactating * Subjects who are participating in a clinical study or who have participated in a clinical study involving administration of an investigational drug (new molecular entity) in the past 3 months. * Subjects with a significant history of drug allergy to similar drug or its excipients. * Subjects who have any clinically significant medical history or significant allergic condition in the opinion of the investigator * Subjects with clinically significant out of range PTH or serum calcium or vitamin D levels as judged by the investigator. Subjects with current or a history of hypocalcaemia * Subjects who; are known to have serum hepatitis, are carriers of the hepatitis B surface antigen (HBsAg) are carriers of the hepatitis C antibody, have a positive result to the test for HIV antibodies. * Subjects who have previously taken part in or withdrawn from this study post first drug administration. * Other standard exclusion criteria like Subjects who have a clinically significant disorder or a significant abnormal laboratory finding, in the opinion of the Investigator.